Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.69 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lofentanil SCHEMBL1649486 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| Lofentanil SCHEMBL1952939 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| Lofentanil SCHEMBL11565496 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| Lofentanil SCHEMBL30637157 | 0.98 | OPRM1 (0.96) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| Lofentanil SCHEMBL123003 | 0.98 | OPRM1 (0.96) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| Lofentanil SCHEMBL29361613 | 0.98 | OPRM1 (0.96) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| SCHEMBL11567176 | 0.91 | OPRM1 (0.83) | OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL11567179 | 0.91 | OPRM1 (0.83) | OPRM1OPRK1OPRL1OPRD1 | |
| Lofentanil SCHEMBL18730637 | 0.90 | OPRM1 (0.81) | OPRM1OPRK1OPRL1OPRD1CACNA1C | |
| SCHEMBL11565454 | 0.90 | OPRM1 (0.82) | OPRM1OPRK1OPRL1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8226 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| US-20250205146-A1 | GRAPHENE-BASED DRUG DELIVERY DEVICE FOR MUCOSAL AND TRANSMUCOSAL ADMINISTRATION | SISSA - SCUOLA INTERNAZIONALE SUPERIORE DI STUDI AVANZATI (IT) | 2025-06-26 | — | — | US | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4493150-A1 | GRAPHENE-BASED DRUG DELIVERY DEVICE FOR MUCOSAL AND TRANSMUCOSAL ADMINISTRATION | SISSA - Scuola Internazionale Superiore di Studi Avanzati (IT) | 2025-01-22 | — | — | EP | claimed |
| US-20240415832-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-12-19 | — | — | US | claimed |
| EP-0647448-A1 | Orally administrable opioid formulations having extended duration of effect | Euroceltique S.A. (LU) | 1995-04-12 | — | — | EP | claimed |
| US-5288498-A | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1994-02-22 | — | — | US | claimed |
| US-5288497-A | Compositions of oral dissolvable medicaments | THE UNIVERSITY OF UTAH (US) | 1994-02-22 | — | — | US | claimed |
| EP-0441833-B1 | DOSAGE FORM HAVING REDUCED ABUSE POTENTIAL | ALZA CORPORATION (US) | 1993-09-08 | — | — | EP | claimed |
| US-5236714-A | Administering abuse substance in permeable form in conjunction with an antagonist in impermeable form; eliminates immediate \"high\" without diminishing therapeutic value | ALZA CORPORATION (US) | 1993-08-17 | — | — | US | claimed |
| US-5180716-A | Improved bioactivity, side effect reduction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-01-19 | — | — | US | claimed |
| WO-1992002256-A1 | CYCLODEXTRIN COMPLEXES FOR NEURAXIAL ADMINISTRATION OF DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-02-20 | — | — | WO | claimed |
| EP-0200490-B1 | COMPOSITIONS FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1991-03-20 | — | — | EP | claimed |
| US-4822802-A | TRANSDERMAL DELIVERY | ALZA CORPORATION (US) | 1989-04-18 | — | — | US | claimed |
| EP-0200490-A2 | Compositions for noninvasive administration of sedatives, analgesics, and anesthetics | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1986-11-05 | — | — | EP | claimed |